SLC5A2 and type 1 diabetes mellitus: There is an unmet need for cardiovascular prevention in people with type 1 diabetes, as they are deprived of the benefits of new antihyperglycemic drugs, such as SGLT-2 inhibitors, which have been proven in other populations.